Press

BDD signs agreement with Innovation Pharmaceuticals for Advanced Oral Tablet Technology in Treating

BEVERLY, Mass., June 06, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, has signed an agreement with BDD Pharma, an award-winning drug delivery company specializing in modified and controlled release oral formulations, to immediately begin the development of tablets for targeted oral delivery of Brilacidin to the colon. To develop the oral formulation, BDD Pharma will utilize its patented OralogiK™ tablet technology, which employs controlled erosion of a time-dependent barrier layer during small intestine transit to provide effective colon targeting. BDD’s OralogiK™ technology has been specifically designed to wor

Featured Posts
Recent Posts
Archive
Follow Us
  • LinkedIn Social Icon
  • Twitter Basic Square

          BDD Ltd

 

CLINICAL SITE:   BDD Pharma Ltd

Glasgow Royal Infirmary

84 Castle St

Glasgow

G4 0SF, UK

FORMULATION SITE:  BDD Pharma Ltd

Bio-City Scotland

Bo'ness Road

Chapelhall, Newhouse

ML1 5UH, UK

Contact Us

Clinical Site. +44 (0)141 552 8791

Formulation site. +44 (0)141 552 7752

email. enquiries@bddpharma.com

 

Social Media

  • LinkedIn - White Circle
  • Twitter - White Circle
  • YouTube - White Circle
  • Facebook - White Circle

Registered in Scotland No. 212868        Privacy Policy     Acceptable Use     Terms of Use   

@2020 BDD Ltd